Immunic Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Immunic Therapeutics's estimated annual revenue is currently $13.6M per year.(i)
  • Immunic Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Immunic Therapeutics has 88 Employees.(i)
  • Immunic Therapeutics grew their employee count by 21% last year.

Immunic Therapeutics's People

NameTitleEmail/Phone
1
VP, Program Management & Clinical Development OperationsReveal Email/Phone
2
Head Intellectual PropertyReveal Email/Phone
3
Head Investor Relations and CommunicationsReveal Email/Phone
4
Chief Scientific OfficerReveal Email/Phone
5
Chief Financial OfficerReveal Email/Phone
6
CEO, President and DirectorReveal Email/Phone
7
Senior Medical DirectorReveal Email/Phone
8
Co-Founder & Chief Medical OfficerReveal Email/Phone
9
Executive Assistant / Office ManagerReveal Email/Phone
10
Manager Corporate DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-20%N/AN/A
#2
$6.7M438%N/AN/A
#3
$34.4M222-1%N/AN/A
#4
$5.2M670%$10MN/A
#5
$2M130%N/AN/A
#6
$7.5M370%$51.6MN/A
#7
$0.3M2-50%N/AN/A
#8
$4.3M21-16%$3.3MN/A
#9
$3.6M230%N/AN/A
#10
$4.3M56-8%$118MN/A
Add Company

What Is Immunic Therapeutics?

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis.

keywords:N/A

N/A

Total Funding

88

Number of Employees

$13.6M

Revenue (est)

21%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Immunic Therapeutics News

2022-04-19 - Primary Sclerosing Cholangitis Pipeline: Therapeutic ...

The major Primary Sclerosing Cholangitis companies include Gilead Sciences, Immunic, Dr Falk Pharma, Pliant Therapeutics,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$12.8M885%$40.2M
#2
$22.1M884%N/A
#3
$20M887%N/A
#4
$3.5M8925%$3.7M
#5
$3.5M9067%N/A